Mesoblast (NASDAQ:MESO) Sees Unusually-High Trading Volume – Time to Buy?

Mesoblast Limited (NASDAQ:MESO) saw unusually-strong trading volume on Friday . Approximately 419,400 shares were traded during trading, a decline of 21% from the previous session’s volume of 532,140 shares.The stock last traded at $17.18 and had previously closed at $17.90.

Analyst Ratings Changes

A number of research analysts recently issued reports on MESO shares. Piper Sandler boosted their target price on shares of Mesoblast from $11.00 to $15.00 and gave the company an “overweight” rating in a research report on Thursday, December 19th. Maxim Group upgraded Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research note on Tuesday, September 24th. Finally, Jefferies Financial Group cut Mesoblast from a “buy” rating to a “hold” rating in a research report on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $13.50.

Mesoblast Price Performance

The business’s fifty day simple moving average is $13.25 and its two-hundred day simple moving average is $9.47. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18.

Hedge Funds Weigh In On Mesoblast

Large investors have recently bought and sold shares of the business. Signaturefd LLC grew its holdings in Mesoblast by 128.7% in the third quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock valued at $45,000 after purchasing an additional 3,099 shares during the period. Perkins Coie Trust Co grew its stake in Mesoblast by 15.0% in the 3rd quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock valued at $94,000 after acquiring an additional 1,500 shares during the period. Rathbones Group PLC purchased a new stake in Mesoblast in the 2nd quarter worth $95,000. XTX Topco Ltd acquired a new position in Mesoblast during the second quarter worth $103,000. Finally, GAMMA Investing LLC lifted its holdings in Mesoblast by 22.1% during the fourth quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock valued at $133,000 after purchasing an additional 1,213 shares in the last quarter. Institutional investors and hedge funds own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.